Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus

Ernest Brahn, Sarah Lee, Alexandra Lucas, Douglas McFadden, Colin MaCaulay

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Many viruses encode virulence factors to facilitate their own survival by modulating a host's inflammatory response. One of these factors, secreted from cells infected with myxoma virus, is the serine proteinase inhibitor (serpin) Serp-1. Because Serp-1 had demonstrated anti-inflammatory properties in arterial injury models and viral infections, it was cloned and evaluated for therapeutic efficacy in collagen-induced arthritis (CIA). Clinical severity was significantly lower in the Serp-1 protocols (p < 0.0001) and blinded radiographs indicated that the Serp-1 group had significantly less erosions than the controls (p < 0.01). Delayed-type hypersensitivity was lower in the Serp-1 group but antibody titers to type II collagen were not significantly altered. Recipients had minimal histopathologic synovial changes and did not develop neutralizing antibodies to Serp-1. These results indicate that Serp-1 impedes the pathogenesis of CIA and suggests that the therapeutic potential of serine proteinase inhibitors in inflammatory joint diseases, such as rheumatoid arthritis, should be investigated further.

Original languageEnglish (US)
Pages (from-to)254-263
Number of pages10
JournalClinical Immunology
Volume153
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Myxoma virus
Serine Proteinase Inhibitors
Experimental Arthritis
Collagen Type II
Joint Diseases
Delayed Hypersensitivity
Virulence Factors
Virus Diseases
Neutralizing Antibodies
Rheumatoid Arthritis
Anti-Inflammatory Agents
Viruses
Antibodies
Wounds and Injuries
Therapeutics

Keywords

  • Collagen arthritis
  • Immunotherapy
  • Myxoma
  • Rheumatoid
  • Serpin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus. / Brahn, Ernest; Lee, Sarah; Lucas, Alexandra; McFadden, Douglas; MaCaulay, Colin.

In: Clinical Immunology, Vol. 153, No. 2, 01.01.2014, p. 254-263.

Research output: Contribution to journalArticle

Brahn, Ernest ; Lee, Sarah ; Lucas, Alexandra ; McFadden, Douglas ; MaCaulay, Colin. / Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus. In: Clinical Immunology. 2014 ; Vol. 153, No. 2. pp. 254-263.
@article{6c671ad90a5444568185580c58507b3d,
title = "Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus",
abstract = "Many viruses encode virulence factors to facilitate their own survival by modulating a host's inflammatory response. One of these factors, secreted from cells infected with myxoma virus, is the serine proteinase inhibitor (serpin) Serp-1. Because Serp-1 had demonstrated anti-inflammatory properties in arterial injury models and viral infections, it was cloned and evaluated for therapeutic efficacy in collagen-induced arthritis (CIA). Clinical severity was significantly lower in the Serp-1 protocols (p < 0.0001) and blinded radiographs indicated that the Serp-1 group had significantly less erosions than the controls (p < 0.01). Delayed-type hypersensitivity was lower in the Serp-1 group but antibody titers to type II collagen were not significantly altered. Recipients had minimal histopathologic synovial changes and did not develop neutralizing antibodies to Serp-1. These results indicate that Serp-1 impedes the pathogenesis of CIA and suggests that the therapeutic potential of serine proteinase inhibitors in inflammatory joint diseases, such as rheumatoid arthritis, should be investigated further.",
keywords = "Collagen arthritis, Immunotherapy, Myxoma, Rheumatoid, Serpin",
author = "Ernest Brahn and Sarah Lee and Alexandra Lucas and Douglas McFadden and Colin MaCaulay",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.clim.2014.05.003",
language = "English (US)",
volume = "153",
pages = "254--263",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus

AU - Brahn, Ernest

AU - Lee, Sarah

AU - Lucas, Alexandra

AU - McFadden, Douglas

AU - MaCaulay, Colin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Many viruses encode virulence factors to facilitate their own survival by modulating a host's inflammatory response. One of these factors, secreted from cells infected with myxoma virus, is the serine proteinase inhibitor (serpin) Serp-1. Because Serp-1 had demonstrated anti-inflammatory properties in arterial injury models and viral infections, it was cloned and evaluated for therapeutic efficacy in collagen-induced arthritis (CIA). Clinical severity was significantly lower in the Serp-1 protocols (p < 0.0001) and blinded radiographs indicated that the Serp-1 group had significantly less erosions than the controls (p < 0.01). Delayed-type hypersensitivity was lower in the Serp-1 group but antibody titers to type II collagen were not significantly altered. Recipients had minimal histopathologic synovial changes and did not develop neutralizing antibodies to Serp-1. These results indicate that Serp-1 impedes the pathogenesis of CIA and suggests that the therapeutic potential of serine proteinase inhibitors in inflammatory joint diseases, such as rheumatoid arthritis, should be investigated further.

AB - Many viruses encode virulence factors to facilitate their own survival by modulating a host's inflammatory response. One of these factors, secreted from cells infected with myxoma virus, is the serine proteinase inhibitor (serpin) Serp-1. Because Serp-1 had demonstrated anti-inflammatory properties in arterial injury models and viral infections, it was cloned and evaluated for therapeutic efficacy in collagen-induced arthritis (CIA). Clinical severity was significantly lower in the Serp-1 protocols (p < 0.0001) and blinded radiographs indicated that the Serp-1 group had significantly less erosions than the controls (p < 0.01). Delayed-type hypersensitivity was lower in the Serp-1 group but antibody titers to type II collagen were not significantly altered. Recipients had minimal histopathologic synovial changes and did not develop neutralizing antibodies to Serp-1. These results indicate that Serp-1 impedes the pathogenesis of CIA and suggests that the therapeutic potential of serine proteinase inhibitors in inflammatory joint diseases, such as rheumatoid arthritis, should be investigated further.

KW - Collagen arthritis

KW - Immunotherapy

KW - Myxoma

KW - Rheumatoid

KW - Serpin

UR - http://www.scopus.com/inward/record.url?scp=84902505920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902505920&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2014.05.003

DO - 10.1016/j.clim.2014.05.003

M3 - Article

C2 - 24845791

AN - SCOPUS:84902505920

VL - 153

SP - 254

EP - 263

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 2

ER -